Bdr Pharmaceuticals
Bdr Pharmaceuticals, a prominent player in the pharmaceutical industry, is headquartered in India and operates extensively across various regions. Founded in 2001, the company has established itself as a leader in the development and manufacturing of high-quality generic and specialty pharmaceuticals. Bdr Pharmaceuticals focuses on therapeutic areas such as oncology, cardiology, and neurology, offering a diverse portfolio of products that are distinguished by their efficacy and affordability. The company is recognised for its commitment to innovation and quality, achieving several milestones in research and development. With a strong market position, Bdr Pharmaceuticals has garnered accolades for its contributions to healthcare, ensuring access to essential medications for patients worldwide. Its dedication to excellence continues to drive its growth and reputation in the global pharmaceutical landscape.
DitchCarbon Score
How does Bdr Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bdr Pharmaceuticals's score of 14 is lower than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bdr Pharmaceuticals's reported carbon emissions
Bdr Pharmaceuticals, headquartered in India, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Bdr Pharmaceuticals may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. In the context of the pharmaceutical industry, companies are increasingly expected to adopt robust climate strategies and disclose their emissions data. As Bdr Pharmaceuticals moves forward, establishing measurable targets and participating in initiatives such as the Science Based Targets initiative (SBTi) could enhance its sustainability profile and align it with industry standards.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bdr Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
